At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3 enrolled
Drug / intervention
Belataceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific Human Leukocyte Antigen (HLA) Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients
In Brief
A Phase 4 clinical trial evaluating Belatacept for Kidney Transplantation. Completed, enrolled 3 participants across 1 site.
Detailed Summary
The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedMar 2014
Primary CompletionJul 2016
TodayJul 2026
First PostedMar 5, 2014
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.3 years ago
Interventions
Belataceptdrug
Patients will be converted from their MMF to Belatacept